AGP Executive Report
Last update: 5 hours agoBiopharma Deal: SERB Pharmaceuticals is buying Idefirix® (imlifidase) exclusive EU/UK/CH/NO/LI/IS and MENA development & commercialization rights from Hansa Biopharma for €115 million, targeting desensitisation for highly sensitised kidney-transplant patients. Nordic-India Business Push: In Oslo, Norwegian industry urged Modi to fix “ground level” regulatory friction—streamlining approvals and easing fertilizer registration timelines—while leaders unveiled a Green Strategic Partnership spanning clean energy, climate resilience, blue economy and green shipping. Energy Diplomacy Under Pressure: The same visit frames cooperation around energy security as global supply risks persist, with India speeding wind and battery storage approvals and Norway leaning on renewables. Trade & Order Debate: Brazil signals it will defend multilateralism in public while preparing to “play alone” as the system faces its worst crisis since the 1990s. Liechtenstein Angle: The SERB acquisition explicitly includes Liechtenstein, tying the country to a major transplant-focused pharma expansion.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
